Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AMRI stock takes a hit

September 12, 2005 | A version of this story appeared in Volume 83, Issue 37

Contract research firm Albany Molecular Research Inc. saw its stock drop 23% to $12.99 per share last Tuesday following the announcement that Barr Pharmaceuticals and Teva Pharmaceutical Industries plan to launch a generic version of Sanofi-Aventis' allergy drug Allegra. AMRI holds the patent on fexofenadine, Allegra's active ingredient. Bank of America Securities analyst Frank H. Pinkerton writes that Allegra royalties netted AMRI $43 million in 2004 and had been expected to reach $47 million in 2005. He now expects royalties for this year to total $40 million. Sanofi has filed patent-infringement lawsuits against both Barr and Teva that are not expected to be settled until next year.

 

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.